# US 2013/0280329 A1 · Methods and compositions for rnai-based cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280329 A1
- Document ID: US20130280329A1
- Status: Published application
- Kind: A1
- Application number: 13/451,231
- Filed: 2012-04-19
- Published: 2013-10-24
- Earliest claimed: 2012-04-19
- Assignees: Silenseed Ltd.
- Inventors: Amotz Shemi; Elina Zorde Khvalevsky
- Web page: https://patentgrep.com/patent/US20130280329A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention generally concerns methods and compositions for treating mutated K-ras expressing cancers.

## Claims

### Claim 1

A millimeter-scale drug delivery device (DDD) comprising:
A. A biodegradable polymeric matrix; and
B. An RNAi (RNA interference) agent incorporated within said biodegradable matrix, wherein said RNAi agent comprises a duplex region, and the nucleotide sequence of the sense strand of said duplex region consists of a sequence selected from SEQ ID No: 1-7:
(SEQ ID No: 1)
GUUGGAGCUGAUGGCG,
(SEQ ID No: 2)
GUUGGAGCUGUUGGCG,
(SEQ ID No: 3)
GUUGGAGCUGCUGGCG,
(SEQ ID No: 4)
GUUGGAGCUAGUGGCG,
(SEQ ID No: 5)
GUUGGAGCUUGUGGCG,
(SEQ ID No: 6)
GUUGGAGCUGGUGACG,
and
(SEQ ID No: 7)
GUUGGAGCUGGUUGCG,
either alone or followed by a sequence selected from
i. UAGGCAAGAGUGCC (SEQ ID No: 8); and
ii. a 5′-fragment of 1-13 nucleotides inclusive of SEQ ID No: 8.

### Claim 2 (depends on 1)

The DDD of claim 1, wherein said 5′ fragment of SEQ ID No: 8 is present in said nucleotide sequence of the sense strand, and said 5′ fragment is at least 3 nucleotides in length; or SEQ ID No: 8 is present in its entirety in said nucleotide sequence of the sense strand.

### Claim 3 (depends on 1)

The DDD of claim 1, wherein said nucleotide sequence of the sense strand of said duplex region consists of a sequence selected from GUUGGAGCUGAUGGCGUAG (SEQ ID No: 9), GUUGGAGCUGUUGGCGUAG (SEQ ID No: 10), GUUGGAGCUGCUGGCGUAG (SEQ ID No: 11), GUUGGAGCUAGUGGCGUAG (SEQ ID No: 12), GUUGGAGCUUGUGGCGUAG (SEQ ID No: 13), and GUUGGAGCUGGUGACGUAG (SEQ ID No: 14), and GUUGGAGCUGGUUGCGUAG (SEQ ID No: 15).

### Claim 4 (depends on 1)

The DDD of claim 1, wherein at least one of the sense strand and the antisense strand further comprises a 1-6-nt 3′-overhang.

### Claim 5 (depends on 1)

The DDD of claim 1, wherein the sense strand and the antisense strand each further comprises a 2-nt 3′-overhang.

### Claim 6 (depends on 5)

The DDD of claim 5, wherein each of said 2-nt 3′ overhangs consists of dTdT.

### Claim 7 (depends on 1)

The DDD of claim 1, wherein said biodegradable polymeric matrix comprises PLA and PGA, wherein said PLA and PGA are present in a ratio equal to or larger than 75:25, or equal to or smaller than 25:75.

### Claim 8 (depends on 1)

The DDD of claim 1, further comprising an additive for modulating drug-polymer hydrophobic-hydrophilic interactions.

### Claim 9 (depends on 1)

The DDD of claim 1, further comprising a pH-modulating additive.

### Claim 10 (depends on 1)

The DDD of claim 1, wherein said DDD is 0.68 mm+/−0.45 mm in diameter and is 2+/−1.5 mm in length.

### Claim 11 (depends on 1)

The DDD of claim 1, wherein said DDD contains between 200-470 micrograms of RNAi agent per DDD.

### Claim 12 (depends on 1)

The DDD of claim 1, wherein said RNAi agent is chemically modified with 2′-OMe or 2′-F.

### Claim 13 (depends on 12)

The DDD of claim 12, wherein the sequences of the sense and antisense strands of said RNAi agent are either:
(SEQ ID No: 37)
A.
5′-GUoUoGGAGCUGAUGGCGoUoAGdTdT
and
(SEQ ID No: 38)
5′-CUACGCCAUCAGCUCCAACdTdT;
OR
(SEQ ID No: 39)
B.
5′-GUoUGGAGCoUGAoUGGCGoUAG
and
(SEQ ID No: 40)
5′-CoUACGCoCAUoCAGCUCoCAAC,
respectively, wherein “o” preceding a residue denotes a 2′-O-Methyl modification of said residue.

### Claim 14 (depends on 1)

The DDD of claim 1, wherein said RNAi agent is conjugated to a cholesterol or α-tocopherol moiety.

### Claim 15 (depends on 1)

The millimeter-scale DDD of claim 1, wherein:
A. said biodegradable matrix comprises PLGA, D-Mannitol, and sodium bicarbonate; and
B. said nucleotide sequence of the sense strand of said RNAi agent is GUUGGAGCUGAUGGCGUAGdTdT (SEQ ID No: 41), and the sequence of the antisense strand of said RNAi agent is CUACGCCAUCAGCUCCAACdTdT (SEQ ID No: 42);
C. no more than 30-50% of said RNAi agent is released during the first 3 weeks in a body tissue in vivo; and
D. the drug load is at least 10%.

### Claim 16 (depends on 1)

A method of treating a patient having a solid tumor expressing a mutated K-ras protein, wherein said mutated K-ras protein comprises a mutation selected from G12D, G12V, G12A, G12S, G12C, G13D, and G13C, comprising the step of administering to said patient the DDD of claim 1, thereby treating a patient having a solid tumor expressing a mutated K-ras protein.

### Claim 17 (depends on 16)

The method of claim 16, wherein said solid tumor is selected from pancreatic tumor, colon tumor, and lung tumor.

### Claim 18 (depends on 16)

The method of claim 16, further comprising the step of administering to said patient a substance selected from pyrimidine analogues, EGFR tyrosine kinase inhibitors, and a subset or all the agents included in FOLFIRINOX, optionally further comprising radiation.

### Claim 19

An RNAi agent, wherein the sequences of the sense and antisense strands of said RNAi agent are either:
(SEQ ID No: 37)
A.
5′-GUoUoGGAGCUGAUGGCGoUoAGdTdT
and
(SEQ ID No: 38)
5′-CUACGCCAUCAGCUCCAACdTdT;
OR
(SEQ ID No: 39)
B.
5′-GUoUGGAGCoUGAoUGGCGoUAG
and
(SEQ ID No: 40)
5′-CoUACGCoCAUoCAGCUCoCAAC,
respectively, wherein “o” denotes a 2′-O-Methyl modification.

### Claim 20 (depends on 19)

A method of treating a patient having a solid tumor expressing a mutated K-ras protein, comprising the step of administering to said patient a medicament comprising the RNAi agent of claim 19, thereby treating a patient having a solid tumor expressing a mutated K-ras protein.

### Claim 21 (depends on 20)

The method of claim 20, further comprising the step of administering to said patient a substance selected from pyrimidine analogues, EGFR tyrosine kinase inhibitors, and a subset or all the agents included in FOLFIRINOX, optionally further comprising radiation.
